Flutamide for Prostate Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Prostate Cancer
Flutamide - Drug
Eligibility
18+
Male
What conditions do you have?
Select

Study Summary

This trial will test if flutamide can help treat prostate cancer by creating double strand breaks in the DNA of cancer cells.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Prostate Cancer

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 6-9 months

6-9 months
time to DNA double strand break

Trial Safety

Safety Progress

1 of 3

Other trials for Prostate Cancer

Side Effects for

Flutamide
38%headache
31%stomach pain
23%dry skin
15%insomnia
15%nausea
15%hot flushes
15%Diarrhea
8%parasthesia
8%dry mouth
8%leg pain
8%fatigue
This histogram enumerates side effects from a completed 2011 Phase 4 trial (NCT00611923) in the Flutamide ARM group. Side effects include: headache with 38%, stomach pain with 31%, dry skin with 23%, insomnia with 15%, nausea with 15%.

Trial Design

2 Treatment Groups

flutamide
1 of 2
placebo
1 of 2
Experimental Treatment
Non-Treatment Group

24 Total Participants · 2 Treatment Groups

Primary Treatment: Flutamide · Has Placebo Group · Phase < 1

flutamide
Drug
Experimental Group · 1 Intervention: Flutamide · Intervention Types: Drug
placebo
Other
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Other
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Flutamide
FDA approved

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 6-9 months

Who is running the clinical trial?

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsLead Sponsor
534 Previous Clinical Trials
31,088 Total Patients Enrolled
51 Trials studying Prostate Cancer
2,961 Patients Enrolled for Prostate Cancer
Daniel Song, M.D.Principal InvestigatorSKCCC at Johns Hopkins

Eligibility Criteria

Age 18+ · Male Participants · 5 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
At least one biopsy core with Gleason 7 or higher disease.
Clinically palpable disease corresponding to (ipsilateral to) any involved core on biopsy.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 28th, 2021

Last Reviewed: October 30th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.